Article Text

PDF

Review
Belimumab in systemic lupus erythematosus
  1. Andreia Vilas-Boas1,
  2. Sandra A Morais1 and
  3. David A Isenberg2
  1. 1Internal Medicine Department, Hospital Pedro Hispano, Matosinhos, Portugal
  2. 2Centre for Rheumatology, University College London Hospitals, London, UK
  1. Correspondence to David A Isenberg; d.isenberg{at}ucl.ac.uk

Abstract

Systemic lupus erythematosus (SLE) is one of the most challenging autoimmune disorders with a complex pathophysiology and diverse clinical presentation. Many drugs have been used to treat SLE with suboptimal results, especially in patients with moderate-to-severe disease. Belimumab is the first biological drug to be approved for the treatment of SLE in more than 50 years. This monoclonal antibody blocks B-cell activating factor, a cytokine important for B-cell differentiation and survival. In this review we focus on the activity of belimumab in patients with SLE and discuss the controversies of its use.

Statistics from Altmetric.com

  • Received January 21, 2015.
  • Accepted February 11, 2015.
View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.